Plasmodium falciparum pre-erythrocytic antigen

Plasmodium falciparum pre-erythrocytic antigens are a heterogeneous group of parasite proteins expressed during the sporozoite and liver (pre-blood) phases of the malaria parasite life cycle[1][2][3][4][5][6][7][8][9]. These proteins include well-described examples such as Circumsporozoite protein (CSP), Thrombospondin-related anonymous protein (TRAP/SSP2), Liver stage antigen-1 (LSA-1), Liver stage antigen-3 (LSA-3), Sporozoite threonine- and asparagine-rich protein (STARP), and Early transcribed membrane proteins (ETRAMPs)[1][2][4][6][9]. These antigens are crucial for parasite infectiousness and for development in the liver; they are the primary targets of both natural and vaccine-induced immune responses aiming for sterile protection against malaria by blocking the parasite before it reaches the blood stage. Immunity is mainly mediated via strong CD8^+ T cell responses (for liver-expressed antigens) and neutralizing antibodies (primarily to sporozoite surface antigens)[3][7][8]. Several vaccine candidates, including the RTS,S/AS01 vaccine (which targets CSP), are designed to elicit immunity to these antigens, though no current malaria vaccine achieves full sterilizing protection in all populations[2][3][6][9]. "P. falciparum pre-erythrocytic antigens" is a collective name, not a single defined molecule, receptor, or conventional druggable target class; it encompasses a family of unrelated proteins, each with specific names, functions, and immunological relevance. For structured data, it is preferable to name individual antigens (e.g., Circumsporozoite protein, Liver stage antigen-1) when possible[1][2][3][4][6][9].

Other names

Pre-erythrocytic antigens of Plasmodium falciparumP. falciparum sporozoite antigensP. falciparum liver-stage antigens

Induction of sterilizing or partial immunity when targeted by vaccines; immune-mediated clearance or inhibition of liver-stage infection Antibodies prevent hepatocyte invasion CD8^+ T cells kill infected hepatocytes presenting antigen via MHC-I